Business Wire

WisdomTree Announces Private Offering of $130.0 Million of Convertible Senior Notes

Share

WisdomTree, Inc. (NYSE: WT) (“WisdomTree”), a global financial innovator, today announced its intention to offer, subject to market conditions and other factors, $130.0 million aggregate principal amount of its convertible senior notes due 2028 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). WisdomTree also expects to grant the initial purchaser of the notes an option to purchase, for settlement during a period of 13 days from, and including, the date the notes are first issued, up to an additional $20.0 million aggregate principal amount of the notes.

WisdomTree intends to use a portion of the net proceeds from the offering to finance the concurrent repurchase of up to approximately $115.0 million in aggregate principal amount of its 4.25% convertible senior notes due 2023 (the “2023 notes”) as described below, with the remainder to be used for working capital and other general corporate purposes. Any remaining 2023 notes outstanding will be settled no later than maturity.

Prior to May 15, 2028, the notes will be convertible at the option of the holders of the notes only upon the satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, WisdomTree will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at WisdomTree’s election, in respect of the remainder, if any, of WisdomTree’s conversion obligation in excess of the aggregate principal amount of the notes being converted. The notes will also be redeemable, in whole or in part, for cash at WisdomTree’s option at any time, and from time to time, on or after August 20, 2025 in certain circumstances. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.

Contemporaneously with the pricing of the notes in the offering, WisdomTree intends to enter into separate privately negotiated transactions with certain holders of the 2023 notes to repurchase up to approximately $115.0 million in aggregate principal amount of the 2023 notes on terms to be negotiated with such holders (each a “note repurchase” and collectively the “2023 notes repurchases”). The terms of each note repurchase are anticipated to be negotiated with certain holders of 2023 notes on an individual basis and will depend on several factors, including the market price of WisdomTree’s common stock and the trading price of the 2023 notes at the time of each such note repurchase. No assurance can be given as to how much, if any, of the 2023 notes will be repurchased or the terms on which they will be repurchased. The consideration for any such note repurchases will be cash financed with a portion of the net proceeds from the offering. Any remaining 2023 notes outstanding will be settled no later than maturity.

WisdomTree expects that certain holders of 2023 notes that sell their 2023 notes in negotiated transactions with WisdomTree may enter into or unwind various derivatives with respect to WisdomTree’s common stock and/or purchase shares of its common stock in the market. The amount of WisdomTree’s common stock that such holders purchase may be substantial in relation to the historic average daily trading volume of the common stock. In addition, WisdomTree expects that certain purchasers of the notes offered in the offering may establish a short position with respect to its common stock by short selling the common stock or by entering into short derivative positions with respect to the common stock, in each case, in connection with the offering. The net effect of the above market activities by holders of 2023 notes and purchasers of the notes offered in the offering could increase (or reduce the size of any decrease in) or decrease (or reduce the size of any increase in) the market price of WisdomTree’s common stock and/or the market price of the notes offered in the offering, and WisdomTree cannot predict the magnitude of such market activities or the overall effect they will have on the market price of the notes and/or the market price of its common stock.

The notes will only be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The notes and the common stock issuable upon conversion of the notes, if any, have not been and will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from such registration requirements.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About WisdomTree

WisdomTree is a global financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. We empower investors to shape their future and support financial professionals to better serve their clients and grow their businesses. WisdomTree is leveraging the latest financial infrastructure to create products that provide access, transparency and an enhanced user experience. Building on our heritage of innovation, we are also developing next-generation digital products and structures, including digital funds and tokenized assets, as well as our blockchain-native digital wallet, WisdomTree Prime™.

WisdomTree currently has approximately $88.1 billion in assets under management globally.

WisdomTree® is the marketing name for WisdomTree, Inc. and its subsidiaries worldwide.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that are based on WisdomTree’s management’s beliefs and assumptions and on information currently available to management. Although WisdomTree believes that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or WisdomTree’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond WisdomTree’s control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, the risks described below. If one or more of these or other risks or uncertainties occur, or if WisdomTree’s underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this press release completely and with the understanding that WisdomTree’s actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

In particular, forward-looking statements in this press release may include statements about the proposed terms of the notes, the size of the notes offering, including the option to purchase additional notes to be granted to the initial purchaser, the expected use of the proceeds from the sale of the notes and the potential effects of the 2023 notes repurchases on WisdomTree’s common stock and the market price of the notes, and other statements contained in this press release that are not historical facts. Forward-looking statements are subject to many risks and uncertainties, including without limitation, risks related to or associated with whether WisdomTree will consummate the offering of the notes on the expected terms, or at all, which could differ or change based upon market conditions or other reasons, and the other risks set forth under the caption “Risk Factors” in WisdomTree’s Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.

Category: Business Update

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
WisdomTree, Inc.
Jessica Zaloom
+1.917.267.3735
jzaloom@wisdomtree.com / wisdomtree@fullyvested.com

Investor Relations
WisdomTree, Inc.
Jeremy Campbell
+1.646.522.2602
Jeremy.Campbell@wisdomtree.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)17.9.2025 22:46:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commission’s approval of vimseltinib for TGCT is a significant milestone for Deciphera, ONO, and TGCT patients across the European Union who are in need of a non-invasive treatment option. We are excited to leverage our global commercial infrastructure to bring vimseltinib to these patients,” said Ryota Udagawa, President and Chief Executive Officer of Deciphera. “We look forward to working with health authorities to ensure all eligible patients who can benefit from vimseltinib have access as quickly as p

Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder17.9.2025 19:09:00 EEST | Press release

Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909723150/en/ Global Appeal Post-pandemic travellers prioritize remote, nature-led adventures and privacy-forward itineraries [1][3]. Adventure tourism is on a sharp upswing globally [5], while research highlights how social media and influencer content accelerate demand for marquee mountain experiences [7]. At the same time, heli-sports are forecast to expand steadily across Canada, Europe, APAC, and South America [8]. World’s Best Heli-Ski NEH operates in BC’s Ske

Bacardi Announces Internal Leadership Moves Within People and Supply Chain Organizations17.9.2025 17:35:00 EEST | Press release

Bacardi Limited, the world’s largest privately held international spirits company, announces several internal moves, underscoring the company’s global approach to leadership development and a commitment to talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917778482/en/ Bacardi announces new roles for Dave Ingram and Nicole Zukowski. Dave Ingram has been appointed to the role of Chief People & Business Transformation Officer, responsible for delivering the next chapter for building an organization that is fit for the future. In this role, Dave will continue to prioritize talent management, succession planning, performance management, and capability building which are core to setting a legacy of more than 163 years for the success of generations to come. Dave, a member of the Bacardi Global Leadership Team, most recently served as Chief Supply Chain Officer, where he led the end-to-end supply chain for the company’s po

Andersen Consulting Adds Collaborating Firm Charter17.9.2025 16:30:00 EEST | Press release

Andersen Consulting expands its digital transformation capabilities through a Collaboration Agreement with Charter, a Canadian consulting firm that specializes in IT strategy, managed services, and application delivery. Established in 1997, Charter delivers technology projects with a business-first mindset and deep technical expertise, offering IT advisory, cloud infrastructure, cybersecurity, application development, project delivery, and business architecture. Charter supports traditional enterprise, government, service provider, and mid-market clients with implementation, network infrastructure, and customer-facing applications—delivered through a lifecycle approach from strategy to execution. “Our goal at Charter has always been to remove the complexity from IT and help organizations move with confidence,” said Kelly Michell, president of Charter. “Our collaboration with Andersen Consulting enables us to bring our integrated, business-aligned solutions to new markets and continue d

Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 16:10:00 EEST | Press release

Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed Since May 2025 Delivered with Wildix reseller Focus CX, the rollout shows how agentic voice automation relieves frontline pressure, improves patient experience and provides measurable value. Missed calls remain one of healthcare’s hidden drains. Over a third of new patient calls go unanswered and most never c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye